Mapping the treatment journey following antibody-drug conjugate (ADC) initiation: Sequencing patterns and real world overall survival (rwOS) in non-breast solid tumors in a US community setting.

Changxia Shao; Alisha Monnette Kimble; Juliet Ndukum; Thomas Burke; Peter Kaskel; Senaka Peter; Yue Shentu; Anne C. Deitz; Tanya E. Keenan; Fan Jin; Robert Reid

doi:10.1200/jco.2026.44.16_suppl.e23362

May 28, 2026Journal of Clinical Oncology

Mapping the treatment journey following antibody-drug conjugate (ADC) initiation: Sequencing patterns and real world overall survival (rwOS) in non-breast solid tumors in a US community setting.

View at Publisher

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate treatment sequencing patterns and overall survival in patients with non-breast solid tumors receiving antibody-drug conjugates.
Retrospective observational analysis of patients (N=1592) with bladder, ovarian, non-small cell lung, gastric, or cervical cancer
Data sourced from the iKnowMed EHR database from Jan 2020 to Aug 2024, assessing real-world overall survival based on treatment lines
Median follow-up of 7.6 to 8.1 months for various tumor types.
Median overall survival for bladder cancer was 17.4 months for the first line and 12.6 months for second line or beyond
For ovarian cancer, median overall survival was 19.4 months (first line) and 16.3 months (second line or beyond)
Significant variations in treatment sequencing and survival across the different solid tumor types.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Retrospective study assesses overall survival and treatment sequencing in non-breast solid tumors, suggesting variations in outcomes based on treatment lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shao et al. (2026) studied this question.

synapsesocial.com/papers/6a1a818e0307b7850943366d https://doi.org/10.1200/jco.2026.44.16_suppl.e23362

View at Publisher

Ask AI

Bookmark

Share

Mapping the treatment journey following antibody-drug conjugate (ADC) initiation: Sequencing patterns and real world overall survival (rwOS) in non-breast solid tumors in a US community setting.

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Mapping the treatment journey following antibody-drug conjugate (ADC) initiation: Sequencing patterns and real world overall survival (rwOS) in non-breast solid tumors in a US community setting.

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading